Showing results (101-110 of 128) with videos related to
Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|November 26, 2008
A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in sizeYuji Sakuma, Naoyuki Okamoto, Haruhiro Saito, et al.Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|October 27, 2004
[A case of cT0N2M0 small cell lung cancer with Lambert-Eaton myasthenic syndrome]Jun Tsukiji, Takeshi Kaneko, Haruhiro Saito, et al.American Journal of Clinical Oncology|March 10, 2018
Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809Seiji Niho, Norihiko Ikeda, Hiroshi Michimae, et al.Anticancer Research|December 6, 2015
Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910Kouzo Yamada, Haruhiro Saito, Tetsuro Kondo, et al.Thoracic Cancer|September 9, 2024
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902)Taishi Harada, Tomonari Sasaki, Hidenobu Ishii, et al.BMC Cancer|March 4, 2018
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016Satoshi Ikeda, Terufumi Kato, Takashi Ogura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322Yoshitaka Zenke, Seiji Niho, Shigeki Umemura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2020
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206Hirotsugu Kenmotsu, Seiji Niho, Masahiro Tsuboi, et al.Cancer|February 2, 2016
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trialMasayuki Takeda, Takeharu Yamanaka, Takashi Seto, et al.Pageof 13